12/5
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Neutral
Report
Spyre Therapeutics Announces Grants of Inducement Awards
12/1
08:35 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.
11/26
02:19 pm
syre
Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/17
01:42 pm
syre
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]
Low
Report
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]
11/16
01:08 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
11/9
07:03 pm
syre
Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? [Yahoo! Finance]
Low
Report
Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? [Yahoo! Finance]
11/7
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Low
Report
Spyre Therapeutics Announces Grants of Inducement Awards
11/4
04:05 pm
syre
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/4
04:01 pm
syre
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
Low
Report
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
10/29
04:05 pm
syre
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
Low
Report
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
10/24
08:00 am
syre
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Medium
Report
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
10/15
04:15 pm
syre
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Low
Report
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
10/14
10:30 pm
syre
Spyre Therapeutics (SYRE): Assessing Valuation Following Major Equity Offering and Share Price Surge [Yahoo! Finance]
Low
Report
Spyre Therapeutics (SYRE): Assessing Valuation Following Major Equity Offering and Share Price Surge [Yahoo! Finance]
10/14
01:07 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
10/13
09:07 pm
syre
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
Medium
Report
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
10/13
04:21 pm
syre
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants [Yahoo! Finance]
10/13
04:01 pm
syre
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
High
Report
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
10/6
03:30 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was downgraded by analysts at
Wall Stre
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was downgraded by analysts at
Wall Stre
10/5
09:11 am
syre
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 [Yahoo! Finance]
Medium
Report
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 [Yahoo! Finance]
10/5
09:00 am
syre
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
Medium
Report
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
10/3
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
9/28
03:32 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
9/26
08:05 am
syre
Spyre Therapeutics (NASDAQ:SYRE) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $43.00 price target on the stock.
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $43.00 price target on the stock.
9/24
08:41 pm
syre
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial [Yahoo! Finance]
Medium
Report
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial [Yahoo! Finance]
9/16
08:07 am
syre
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.